
Nanotechnology-Based Vaccine Delivery Systems: Current Advances and Emerging**Applications**

Sumit Kumar

Department of Pharmaceutical Sciences,
Central University of Haryana, Jant-Pali, Mahendergarhdrsumitkumar@cuh.ac<https://doi.org/10.7813/ed83a971>**Abstract**

The emergence of nanotechnology has fundamentally transformed the landscape of modern vaccinology, offering unprecedented control over antigen presentation, immune modulation, and targeted delivery. Conventional vaccine platforms, although historically effective, are frequently limited by poor stability, weak immunogenicity of subunit antigens, the requirement for repeated dosing, and dependence on cold-chain logistics. Nanotechnology-based vaccine delivery systems address these limitations by exploiting the unique physicochemical properties of nanoscale materials, including their high surface-area-to-volume ratio, tunable surface chemistry, and capacity to co-encapsulate antigens and immunostimulatory adjuvants. This review provides a comprehensive and critical synthesis of the principal nanocarrier classes currently employed in vaccine development, encompassing lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, virus-like particles, and self-assembling protein nanoparticles. Particular attention is devoted to the pivotal role of lipid nanoparticles in enabling the clinical success of messenger RNA (mRNA) vaccines against coronavirus disease 2019, an achievement that has catalysed a global reappraisal of nanocarrier-enabled immunization. The mechanisms by which nanoparticles enhance antigen uptake by antigen-presenting cells, promote lymph node trafficking, and shape the balance between humoral and cellular immunity are examined in detail. Emerging applications, including personalized cancer vaccines, mucosal and needle-free immunization, and pandemic-preparedness platforms, are discussed alongside persistent challenges relating to manufacturing scalability, storage stability, biosafety, and regulatory harmonization. By integrating findings from recent preclinical and clinical investigations published between 2015 and 2024, this review highlights the trajectory of the field and identifies the translational hurdles that must be surmounted to realise the full potential of nanotechnology in next-generation vaccines. Collectively, the evidence indicates that rationally engineered nanocarriers will

remain central to the development of safe, potent, and broadly deployable vaccines against infectious diseases and cancer.

Keywords: *nanotechnology; vaccine delivery; lipid nanoparticles; mRNA vaccines; polymeric nanoparticles; adjuvants; immunization; nanomedicine*

1. Introduction

Vaccination remains one of the most cost-effective and impactful interventions in the history of public health, credited with the eradication of smallpox, the near-elimination of poliomyelitis, and a dramatic reduction in the global burden of numerous infectious diseases. Despite these achievements, the development of vaccines against complex, rapidly mutating, or intracellular pathogens continues to present formidable scientific challenges. Traditional vaccine strategies based on live-attenuated or inactivated whole organisms, while effective for many diseases, carry inherent limitations relating to safety, reactogenicity, and the difficulty of manufacturing at scale (Pardi et al., 2018). The transition toward subunit and nucleic-acid-based vaccines has improved safety profiles but introduced new problems, most notably the poor intrinsic immunogenicity of purified antigens and the extracellular instability of nucleic acids. It is within this context that nanotechnology has emerged as a transformative enabling platform, providing sophisticated tools to overcome the biological barriers that have historically constrained vaccine design (Reichmuth et al., 2016).

The convergence of materials science, immunology, and molecular biology has given rise to a diverse array of nanoscale delivery vehicles capable of protecting fragile antigens, controlling their spatiotemporal release, and directing them toward the immune cells and tissues most relevant to protective immunity. The unprecedented speed with which lipid nanoparticle-formulated mRNA vaccines were developed and deployed during the coronavirus disease 2019 pandemic served as a powerful demonstration of the maturity and promise of this field (Hou et al., 2021). This review examines the scientific foundations, current advances, and emerging applications of nanotechnology-based vaccine delivery systems, situating recent developments within the broader trajectory of nanomedicine.

Nanotechnology, defined broadly as the manipulation of matter at dimensions typically below one hundred nanometres, has permeated numerous domains of biomedical science over the past two

decades. Its application to vaccinology is grounded in the observation that the immune system evolved to detect and respond to particulate threats of precisely this scale. Whereas soluble antigens are often rapidly cleared and weakly immunogenic, antigens associated with nanoscale carriers are retained more effectively, presented more efficiently, and accompanied by contextual cues that shape the ensuing response. The deliberate engineering of these carriers thus permits a form of immunological programming that was scarcely conceivable in the era of whole-organism vaccines. As the discipline has matured, the emphasis has shifted from empirical formulation toward rational, structure-guided design informed by a deepening understanding of the interactions between nanomaterials and the immune system (Chatzikleanthous et al., 2021).

1.1 The Rationale for Nanoscale Vaccine Delivery

The immune system has evolved to recognise and respond to pathogens that typically fall within the nanometre-to-micrometre size range. Nanoparticles, with dimensions comparable to those of viruses and subcellular structures, are therefore inherently well-suited to interfacing with immune cells. Particles in the range of approximately 20 to 200 nanometres are efficiently drained through the lymphatic system to reach lymph nodes, where the initiation of adaptive immune responses occurs (Bachmann & Jennings, 2010). By presenting antigens in a repetitive, multivalent array that mimics the surface of a pathogen, nanoparticles can crosslink B-cell receptors and trigger robust humoral responses. Moreover, the particulate nature of these carriers promotes efficient uptake by professional antigen-presenting cells such as dendritic cells and macrophages, facilitating antigen processing and presentation on both major histocompatibility complex class I and class II pathways (Irvine et al., 2015). This dual capacity to stimulate humoral and cellular immunity constitutes a fundamental advantage over many soluble antigen formulations.

Beyond their favourable dimensions, nanoparticles confer a series of pharmacological benefits that address longstanding shortcomings of conventional vaccines. Encapsulation within a nanocarrier shields labile antigens and nucleic acids from enzymatic degradation, extending their half-life in the biological milieu and ensuring that a greater proportion of the administered dose reaches its intended target. The engineered surface of a nanoparticle can be decorated with targeting ligands that direct the cargo toward specific receptors on immune cells, thereby increasing the efficiency and selectivity of delivery. Equally important is the ability of nanocarriers to provide sustained or pulsatile release of

their contents, which can prolong the stimulation of the immune system and reduce the frequency of booster immunizations. These attributes collectively enable a level of control over the immunization process that is difficult, if not impossible, to achieve with soluble antigen formulations alone, and they underpin much of the enthusiasm that surrounds the field (Fan & Moon, 2015).

1.2 Historical Evolution of Nanocarrier Platforms

The application of nanoscale carriers to vaccination has evolved considerably over several decades. Early liposomal formulations, first described in the 1970s, demonstrated that lipid vesicles could enhance antibody responses to encapsulated antigens. These pioneering observations laid the groundwork for the development of more sophisticated systems, including immunostimulating complexes, polymeric microspheres, and virosomes. The clinical approval of virosomal influenza and hepatitis A vaccines validated the concept of nanocarrier-mediated immunization in humans. The subsequent decades witnessed the refinement of biodegradable polymeric particles and the emergence of ionizable lipid chemistries that ultimately enabled the efficient intracellular delivery of nucleic acids (Tenchov et al., 2021). This historical progression reflects a continuous effort to reconcile potency, safety, and manufacturability, culminating in the platforms that dominate contemporary vaccine research.

1.3 Classification of Nanocarrier Systems

Nanotechnology-based vaccine delivery systems can be broadly classified according to their compositional basis. Lipid-based systems, encompassing liposomes and lipid nanoparticles, exploit amphiphilic molecules that self-assemble into ordered structures capable of encapsulating both hydrophilic and hydrophobic cargoes. Polymeric systems, typified by poly(lactic-co-glycolic acid) particles, offer tunable degradation kinetics and sustained antigen release. Inorganic systems, including gold, silica, and aluminium-based nanoparticles, provide rigid scaffolds with well-defined surface chemistry amenable to precise antigen conjugation. Finally, biologically derived systems such as virus-like particles and self-assembling protein nanoparticles harness the structural principles of natural macromolecular assemblies to achieve highly ordered antigen display (Nguyen et al., 2021). Each class presents a distinct balance of advantages and limitations that governs its suitability for particular applications.

The choice of nanocarrier for a given vaccine is dictated by the nature of the antigen, the desired immunological outcome, and practical considerations of cost and manufacturability. Nucleic-acid vaccines, for example, require carriers capable of protecting the genetic material and delivering it to the cytosol, a niche for which lipid nanoparticles are exceptionally well suited. Protein and peptide antigens, by contrast, may benefit from the sustained release afforded by polymeric matrices or from the ordered multivalent display achievable with protein-based scaffolds. The interplay between these compositional categories is increasingly blurred by the advent of hybrid systems that combine elements of multiple classes, such as lipid-polymer hybrid particles that seek to unite the delivery efficiency of lipids with the structural stability of polymers. This growing diversity of platforms reflects the maturation of the field and the recognition that no single carrier is optimal for all applications.

1.4 Scope and Objectives of the Review

This review seeks to provide an integrated account of the current state of nanotechnology-based vaccine delivery, drawing upon the substantial body of literature published between 2015 and 2024. The principal objectives are to delineate the mechanistic basis by which nanocarriers enhance vaccine efficacy, to critically evaluate the major nanoparticle classes with reference to their physicochemical characteristics and immunological performance, and to survey the emerging applications that are reshaping the field. Particular emphasis is placed on translational considerations, including manufacturing, stability, and regulatory dimensions, that will determine whether laboratory advances can be converted into globally accessible products. By synthesising these diverse strands, the review aims to furnish researchers and clinicians with a coherent framework for understanding both the achievements and the outstanding challenges of this rapidly advancing discipline.

2. Literature Review

The literature concerning nanotechnology-based vaccine delivery has expanded exponentially over the past decade, propelled in large part by the extraordinary clinical success of lipid nanoparticle-based mRNA vaccines. This section examines the principal nanocarrier classes in turn, evaluating the evidence relating to their design, immunological mechanisms, and demonstrated applications. Throughout, the discussion integrates findings from both preclinical models and clinical investigations, with supporting data summarised in the accompanying tables.

2.1 Lipid Nanoparticles and the mRNA Vaccine Revolution

The lineage of lipid-based delivery systems can be traced to the liposomes first characterised in the mid-twentieth century, which demonstrated that amphiphilic lipids could spontaneously organise into bilayer vesicles capable of sequestering aqueous and lipophilic cargoes. The subsequent introduction of ionizable lipids, whose ionisation state varies with the surrounding pH, marked a decisive conceptual advance, for it permitted efficient complexation with nucleic acids under acidic formulation conditions while conferring near-neutral charge at physiological pH, thereby mitigating the toxicity historically associated with permanently cationic lipids (Tenchov et al., 2021). This innovation, refined over successive generations of lipid chemistry, ultimately yielded the sophisticated four-component formulations that underpin contemporary messenger RNA vaccines and that transformed a longstanding theoretical aspiration into clinical reality.

Lipid nanoparticles have emerged as the most clinically advanced nanocarrier platform for vaccine delivery, most notably as the delivery vehicle underpinning the messenger RNA vaccines that were deployed globally during the coronavirus disease 2019 pandemic (Hou et al., 2021). A typical lipid nanoparticle comprises four distinct components: an ionizable cationic lipid, a helper phospholipid, cholesterol, and a polyethylene-glycol-conjugated lipid. The ionizable lipid is widely regarded as the most critical determinant of delivery efficiency, as its pH-dependent charge behaviour enables complexation with negatively charged nucleic acids at low pH while remaining largely neutral at physiological pH, thereby minimising toxicity (Schoenmaker et al., 2021). Upon cellular uptake, protonation of the ionizable lipid within the acidifying endosome promotes membrane destabilisation and cytosolic release of the mRNA cargo, a process termed endosomal escape that represents a key rate-limiting step in intracellular delivery.

The remarkable efficacy of the Pfizer-BioNTech and Moderna vaccines, both of which achieved approximately ninety-five per cent protection against symptomatic disease in initial trials, provided compelling validation of the lipid nanoparticle platform (Buschmann et al., 2021). Beyond their role in nucleic acid protection, lipid nanoparticles exhibit intrinsic adjuvant properties; certain ionizable lipids have been shown to stimulate innate immune sensing and to promote the recruitment and activation of antigen-presenting cells at the injection site. This self-adjuvanting behaviour contributes materially to the potent immunogenicity of mRNA-lipid nanoparticle formulations. Ongoing research seeks to refine ionizable lipid structures to improve potency, reduce reactogenicity, and enable delivery

to tissues beyond the liver, thereby broadening the therapeutic scope of the technology (Han et al., 2021).

The manufacture of lipid nanoparticles typically relies on rapid microfluidic mixing, whereby an ethanolic lipid solution is combined with an aqueous phase containing the nucleic acid under precisely controlled flow conditions. This process drives the spontaneous self-assembly of the components into monodisperse particles with an ordered internal structure in which the nucleic acid is sequestered within inverted lipid micelles. The reproducibility and scalability of microfluidic production have proven instrumental in translating lipid nanoparticle vaccines from the laboratory to industrial manufacture, and the technology has been credited with enabling the rapid scale-up witnessed during the recent pandemic (Kim et al., 2021). The physicochemical attributes of the resulting particles, including their size, polydispersity, encapsulation efficiency, and apparent acid dissociation constant, are exquisitely sensitive to formulation and process parameters, and their careful optimisation is central to achieving potent and reproducible immunogenicity.

Table 1. Principal components of lipid nanoparticles and their functional roles in mRNA vaccine delivery.

Component	Representative Example	Primary Function
Ionizable lipid	SM-102, ALC-0315	Complexes mRNA; enables endosomal escape and cytosolic release
Helper phospholipid	DSPC	Stabilises the lipid bilayer and supports particle structure
Cholesterol	Cholesterol	Enhances membrane rigidity, stability, and fusogenicity
PEGylated lipid	ALC-0159, PEG-DMG	Controls particle size; reduces aggregation and opsonisation

Component	Representative Example	Primary Function
Nucleic acid cargo	Nucleoside-modified mRNA	Encodes the target antigen for endogenous expression

The composition of lipid nanoparticles can be systematically tuned to modulate their biodistribution and immunological outcomes. Adjusting the molar ratios of the constituent lipids, altering the length and saturation of lipid tails, and modifying the polyethylene glycol content each exert measurable effects on particle size, surface charge, and cellular tropism (Kularatne et al., 2022). Such structure-activity relationships have become the focus of intensive investigation, as they offer a rational route to optimising delivery for specific applications ranging from prophylactic infectious-disease vaccines to therapeutic cancer immunotherapies.

Table 2. Selected clinical and preclinical lipid nanoparticle vaccine studies (2015–2024).

Vaccine / Platform	Target	Development Stage	Key Outcome
BNT162b2 (Comirnaty)	SARS-CoV-2	Approved	~95% efficacy against symptomatic disease
mRNA-1273 (Spikevax)	SARS-CoV-2	Approved	~94% efficacy; durable neutralising antibodies
mRNA-4157 / V940	Melanoma	Phase III	Reduced recurrence with checkpoint inhibitor
mRNA-1345	Respiratory syncytial virus	Approved	Protective efficacy in older adults

Vaccine / Platform	Target	Development Stage	Key Outcome
mRNA-1010	Seasonal influenza	Phase III	Immunogenic against multiple strains

The clinical portfolio of lipid nanoparticle vaccines has expanded rapidly beyond the initial coronavirus disease 2019 products. Formulations targeting respiratory syncytial virus, seasonal and pandemic influenza, cytomegalovirus, and a range of other pathogens have advanced into late-stage clinical evaluation, and several have secured regulatory approval. This proliferation attests to the versatility of the platform and to the confidence that the extensive real-world experience accumulated during the pandemic has instilled in regulators and developers alike (Verbeke et al., 2021). At the same time, the recognition that lipid nanoparticles preferentially accumulate in the liver following systemic administration has stimulated concerted efforts to achieve extrahepatic and cell-selective delivery, an objective that would substantially broaden the therapeutic reach of the technology and enable applications such as in situ generation of chimeric antigen receptor cells and organ-specific protein replacement.

2.2 Polymeric Nanoparticles and Controlled Antigen Release

Polymeric nanoparticles constitute one of the most versatile and extensively studied classes of vaccine delivery vehicles. Among the various polymers investigated, poly(lactic-co-glycolic acid) has attracted particular attention owing to its biodegradability, biocompatibility, and established regulatory acceptance as a material approved for human use (Gao et al., 2022). Antigens may be encapsulated within the polymeric matrix or adsorbed onto the particle surface, and the gradual hydrolytic degradation of the polymer affords sustained antigen release over prolonged periods. This depot-like behaviour can extend antigen exposure to the immune system, potentially reducing the number of booster doses required to achieve durable immunity (Silva et al., 2016).

A key advantage of polymeric systems lies in the tunability of their degradation kinetics, which can be adjusted by varying the ratio of lactic to glycolic acid monomers and the molecular weight of the polymer. This flexibility permits the rational design of release profiles tailored to specific

immunological objectives. Furthermore, the particle surface can be functionalised with targeting ligands or mucoadhesive coatings to enhance delivery to particular cell populations or mucosal surfaces. Surface modification with chitosan, for instance, has been shown to improve antigen uptake and adjuvant activity in nasal vaccine formulations, offering a route to needle-free immunization (Zhang et al., 2019). The co-encapsulation of antigens with molecular adjuvants such as Toll-like receptor agonists within a single polymeric particle enables the coordinated delivery of both signals to the same antigen-presenting cell, thereby amplifying and shaping the resulting immune response.

Table 3. Comparative properties of major polymeric materials used in vaccine nanoparticles.

Polymer	Origin	Key Advantage	Principal Limitation
PLGA	Synthetic	Tunable, sustained antigen release	Acidic degradation may denature antigen
Chitosan	Natural	Mucoadhesive; enhances mucosal uptake	Batch variability; limited solubility
PLA	Synthetic	Biodegradable; slow degradation	Hydrophobicity limits loading of some antigens
PEI	Synthetic	Efficient nucleic acid condensation	Dose-dependent cytotoxicity
Alginate	Natural	Mild gelation; biocompatible	Weak intrinsic immunogenicity

Despite these advantages, polymeric nanoparticles are not without limitations. The acidic microenvironment generated during the hydrolytic degradation of poly(lactic-co-glycolic acid) can compromise the structural integrity and antigenicity of sensitive protein cargoes, a challenge that has motivated the development of buffering strategies and alternative polymer chemistries (Allahyari& Mohit, 2016). Encapsulation efficiency, burst release, and reproducibility of manufacturing likewise remain areas of active refinement. Nonetheless, the maturity of polymeric nanoparticle technology and

its compatibility with existing manufacturing infrastructure ensure its continued prominence in vaccine research.

Table 4. Immunological mechanisms enhanced by polymeric nanoparticle vaccine delivery.

Mechanism	Immunological Consequence
Depot formation and sustained release	Prolonged antigen exposure and enhanced memory
Efficient dendritic cell uptake	Improved antigen processing and presentation
Cross-presentation on MHC class I	Induction of cytotoxic CD8 ⁺ T-cell responses
Co-delivery of antigen and adjuvant	Coordinated innate and adaptive stimulation
Protection from enzymatic degradation	Increased antigen stability in vivo

A further dimension of polymeric nanoparticle design concerns their exploitation in cancer immunotherapy, where the sustained co-delivery of tumour antigens and potent adjuvants can reprogramme the immunosuppressive tumour microenvironment and elicit durable cytotoxic responses. Poly(lactic-co-glycolic acid) particles engineered to release their payload within the endosomal compartment have been shown to enhance cross-presentation, thereby favouring the generation of antigen-specific CD8-positive T cells that are essential for tumour eradication (Gao et al., 2022). The capacity to surface-functionalise these particles with cationic coatings such as polyethylenimine further permits the condensation and delivery of nucleic-acid adjuvants, illustrating the remarkable adaptability of the polymeric platform (Gu et al., 2019). Collectively, these attributes position polymeric nanoparticles as a mainstay of experimental vaccinology, particularly in applications where prolonged antigen exposure and robust cellular immunity are paramount.

2.3 Inorganic Nanoparticles and Surface-Engineered Platforms

Inorganic nanoparticles, including those based on gold, silica, aluminium, and iron oxide, offer a distinct set of properties that complement the organic carriers discussed above. Their principal

attractions lie in the precise control achievable over their size, shape, and surface chemistry, together with their generally robust structural stability (Dykman & Khlebtsov, 2017). Gold nanoparticles, in particular, provide a chemically inert and readily functionalised scaffold onto which antigens and adjuvants can be conjugated in defined stoichiometries. Their well-characterised surface chemistry permits the covalent attachment of peptides, proteins, and carbohydrates, enabling the construction of multivalent antigen displays that efficiently engage B cells.

Aluminium-based nanoparticles occupy a special position in the history of vaccinology, as aluminium salts have served as the most widely used human vaccine adjuvants for nearly a century. Reformulating aluminium adjuvants at the nanoscale has been shown to alter their interaction with antigens and immune cells, potentially enhancing their immunostimulatory activity while reducing local reactogenicity. Mesoporous silica nanoparticles, meanwhile, offer exceptionally high surface areas and tunable pore structures that permit the loading of large quantities of antigen and the co-delivery of immunomodulatory agents (Wang et al., 2019). Despite these advantages, concerns regarding the biodegradability and long-term biodistribution of certain inorganic materials have tempered enthusiasm and underscored the importance of rigorous biosafety evaluation.

Table 5. Inorganic nanoparticle platforms and their characteristic features in vaccine applications.

Platform	Distinctive Feature	Representative Application
Gold nanoparticles	Precise surface functionalisation	Multivalent peptide antigen display
Mesoporous silica	High surface area and tunable pores	Co-loading of antigen and adjuvant
Aluminium (nano)	Established adjuvant heritage	Enhanced antibody responses
Iron oxide	Magnetic and imaging properties	Trackable delivery; theranostics
Carbon-based	High cargo capacity	Antigen and nucleic acid carriage

The surface engineering of inorganic nanoparticles has become a fertile area of investigation, as the physicochemical characteristics of the particle surface exert a decisive influence on immune recognition. Parameters such as surface charge, hydrophobicity, and ligand density govern the formation of the protein corona that assembles upon contact with biological fluids, which in turn shapes cellular uptake and immune activation (Nel et al., 2009). A nuanced understanding of these nano-bio interactions is increasingly recognised as essential to the rational design of safe and effective inorganic vaccine carriers.

The optical and physical properties unique to certain inorganic materials also enable functionalities that extend beyond antigen delivery. Gold nanoparticles exhibit distinctive plasmonic behaviour that can be harnessed for photothermal immunomodulation, while iron oxide nanoparticles possess magnetic characteristics that permit both directed delivery and non-invasive imaging of vaccine biodistribution (Dykman & Khlebtsov, 2017). Such theranostic capabilities, which unite therapeutic and diagnostic functions within a single platform, are difficult to replicate with purely organic carriers and represent a compelling rationale for continued investigation of inorganic systems. Nevertheless, the translation of these platforms into approved products has been comparatively slow, reflecting persistent uncertainties regarding the metabolism, clearance, and potential accumulation of non-biodegradable materials within the body. Resolving these concerns through the design of biodegradable or renally clearable formulations constitutes an important priority for the field.

2.4 Virus-Like Particles and Self-Assembling Protein Nanoparticles

Virus-like particles represent a biologically inspired approach to nanoparticle vaccine design, harnessing the self-assembling structural proteins of viruses to generate non-infectious particles that faithfully recapitulate the size, geometry, and repetitive surface architecture of native pathogens. Because they lack the viral genome, virus-like particles are inherently incapable of replication, yet they retain the highly ordered antigen display that is exceptionally effective at stimulating B-cell responses (Mohsen et al., 2017). The commercial success of virus-like particle vaccines against hepatitis B and human papillomavirus has firmly established the clinical viability of this platform and demonstrated its capacity to induce durable, protective immunity.

Advances in protein engineering have extended this paradigm through the design of self-assembling protein nanoparticles, in which computationally designed protein subunits spontaneously

organise into defined polyhedral scaffolds. These scaffolds can be decorated with antigens from diverse pathogens, enabling the construction of mosaic and multivalent nanoparticle vaccines capable of eliciting broad immune responses (Marcandalli et al., 2019). Such approaches have shown particular promise in the pursuit of universal vaccines against antigenically variable pathogens, where the simultaneous display of multiple antigenic variants may direct the immune response toward conserved, cross-protective epitopes. The precision and modularity of these engineered systems exemplify the growing convergence of structural biology, computational design, and nanotechnology in contemporary vaccinology.

Table 6. Comparison of virus-like particles and self-assembling protein nanoparticles.

Attribute	Virus-Like Particles	Self-Assembling Protein NPs
Structural basis	Native viral capsid proteins	Computationally designed subunits
Antigen display	Repetitive, high-density	Modular and programmable
Clinical precedent	Established (HBV, HPV)	Emerging (RSV, influenza)
Multivalency	Limited to viral proteins	Readily engineered mosaic display
Manufacturing	Cell-based expression	Recombinant, tunable assembly

Taken together, the biologically derived platforms occupy a distinctive niche within the nanocarrier landscape, combining the safety of subunit vaccines with the immunogenicity conferred by particulate, multivalent antigen presentation. Their principal limitations relate to the complexity of manufacturing and the potential for anti-scaffold immunity, which may attenuate responses upon repeated administration. Continued innovation in scaffold design and expression systems is progressively addressing these constraints.

The application of virus-like particles and engineered protein nanoparticles to the pursuit of broadly protective vaccines merits particular emphasis. Antigenically variable pathogens such as influenza virus and human immunodeficiency virus have long frustrated conventional vaccine

strategies, as the immune response tends to focus upon immunodominant but hypervariable epitopes that mutate readily to evade neutralisation. By displaying multiple antigenic variants, or by presenting conserved subdominant epitopes in an optimised geometric arrangement, nanoparticle scaffolds can redirect the immune response toward regions of the pathogen that are less tolerant of mutation (Marcandalli et al., 2019). This strategy, sometimes termed immunofocusing, exemplifies the sophisticated manner in which the structural precision of engineered nanoparticles can be leveraged to solve problems that have resisted resolution by traditional means, and it lies at the heart of ongoing efforts to develop universal vaccines.

Table 7. Comparative overview of principal nanocarrier classes for vaccine delivery.

Nanocarrier Class	Key Strength	Principal Limitation	Clinical Maturity
Lipid nanoparticles	Efficient nucleic acid delivery	Cold-chain storage requirement	Approved (COVID-19)
Polymeric nanoparticles	Sustained, tunable release	Acidic degradation of antigen	Preclinical / early trials
Inorganic nanoparticles	Precise surface engineering	Biodegradability concerns	Preclinical
Virus-like particles	Potent, ordered antigen display	Complex manufacturing	Approved (HBV, HPV)
Protein nanoparticles	Programmable multivalency	Anti-scaffold immunity	Early clinical

The comparative evaluation of these nanocarrier classes reveals that the field has not converged upon a single dominant platform but rather sustains a diverse ecosystem of complementary technologies. The selection of an appropriate carrier is contingent upon the specific requirements of the target disease, the nature of the antigen, and the constraints of manufacture and distribution. The persistent challenges confronting each class, summarised below, delineate the research priorities that

will shape the next phase of development and determine the pace at which laboratory innovations are translated into deployable products.

Table 8. Key translational challenges across nanoparticle vaccine platforms and prospective solutions.

Challenge	Impact	Prospective Solution
Cold-chain dependence	Limits global distribution	Thermostable and lyophilised formulations
Manufacturing scalability	Constrains supply capacity	Continuous microfluidic production
Extrahepatic targeting	Restricts therapeutic scope	Ligand-directed and charge-tuned lipids
Long-term biosafety	Regulatory uncertainty	Biodegradable and clearable materials
Anti-carrier immunity	Attenuates repeat dosing	Novel scaffolds and PEG alternatives

3. Mechanisms of Immune Enhancement by Nanocarriers

The immunological advantages conferred by nanoparticle-based vaccine delivery arise from a constellation of interrelated mechanisms that operate at the cellular and tissue levels. A foundational mechanism is the enhancement of antigen uptake by professional antigen-presenting cells. The particulate nature of nanocarriers renders them more efficiently internalised than soluble antigens, as dendritic cells and macrophages are specialised to recognise and phagocytose particles within the size range characteristic of pathogens (Irvine et al., 2015). Once internalised, nanoparticle-associated antigens gain access to intracellular processing pathways that culminate in presentation on major histocompatibility complex molecules, thereby priming both helper and cytotoxic T lymphocytes.

A second critical mechanism concerns the trafficking of nanoparticles to secondary lymphoid organs. Particles of appropriate dimensions can drain directly through lymphatic vessels to reach draining lymph nodes, where the density of antigen-presenting cells and naive lymphocytes is greatest (Bachmann & Jennings, 2010). This efficient lymphatic delivery concentrates antigen at the anatomical sites where adaptive immune responses are initiated, amplifying the magnitude and quality of the ensuing response. The controlled release afforded by many nanocarriers further extends the duration of antigen availability, sustaining the stimulation of germinal centres and promoting affinity maturation of antibodies.

A third mechanism relates to the intrinsic and co-delivered adjuvant activity of nanoparticle systems. Certain nanomaterials engage pattern-recognition receptors of the innate immune system directly, providing danger signals that potentiate adaptive immunity. When molecular adjuvants are co-encapsulated with antigen, the nanocarrier ensures that both signals are delivered to the same cell, achieving a spatiotemporal coordination that soluble mixtures cannot replicate (Reichmuth et al., 2016). This capacity to orchestrate the delivery of multiple immunological signals represents perhaps the most powerful and distinctive attribute of nanotechnology-based vaccines, enabling fine control over the character and durability of the immune response.

The geometry and surface topology of nanoparticles further influence the quality of the immune response in ways that are only beginning to be fully understood. The spacing, density, and rigidity with which antigens are arrayed upon a nanoparticle surface govern the strength of B-cell receptor engagement and the efficiency with which germinal centre reactions are initiated. Highly ordered, rigid displays with antigen spacings of a few nanometres appear particularly effective at driving strong and durable antibody responses, a principle that has informed the design of both virus-like particles and engineered protein scaffolds (Bachmann & Jennings, 2010). Surface charge exerts an equally important influence, modulating the interaction of particles with cell membranes, extracellular matrix components, and the protein corona that assembles upon exposure to biological fluids. A comprehensive mechanistic appreciation of these structure-function relationships is indispensable to the rational design of vaccines that elicit responses of the desired magnitude, breadth, and longevity.

Finally, the route and kinetics of nanoparticle administration shape the resulting immunity in clinically significant ways. Intramuscular injection, the most common route for nanoparticle vaccines, establishes a local depot from which particles are gradually released and trafficked to draining lymph

nodes. Alternative routes, including intradermal, subcutaneous, and mucosal administration, engage distinct populations of antigen-presenting cells and can bias the response toward particular effector profiles. The temporal pattern of antigen availability, whether delivered as a single bolus or released in a sustained or pulsatile fashion, likewise influences the maturation of the antibody response. By manipulating these variables, vaccine designers can exert a degree of control over the immune outcome that constitutes one of the defining advantages of the nanotechnology-based approach (Irvine et al., 2015).

4. Emerging Applications and Future Directions

The clinical validation of nanoparticle vaccine platforms has catalysed an expansion of their application beyond conventional prophylactic immunization. Among the most promising frontiers is the development of personalized cancer vaccines, in which patient-specific tumour neoantigens are encoded within nucleic acids and delivered by lipid nanoparticles to elicit tailored anti-tumour immunity. Early-phase clinical trials combining individualised mRNA-lipid nanoparticle vaccines with immune-checkpoint inhibitors have yielded encouraging reductions in disease recurrence, signalling a potential paradigm shift in oncological therapeutics (Rojas et al., 2023). The modularity of nucleic-acid platforms is particularly well suited to this application, as the antigen sequence can be rapidly reprogrammed to match the mutational profile of an individual tumour.

The success of personalized cancer vaccines rests upon a tightly integrated workflow that begins with the sequencing of a patient's tumour to identify somatic mutations, proceeds through the computational prediction of immunogenic neoantigens, and culminates in the synthesis of a bespoke nucleic-acid vaccine formulated within a lipid nanoparticle. The entire process can now be accomplished within a matter of weeks, a timeframe compatible with clinical intervention. Reported results in melanoma and pancreatic cancer have demonstrated that such vaccines can induce robust, durable neoantigen-specific T-cell responses and that these responses correlate with delayed disease recurrence (Rojas et al., 2023). While these findings remain preliminary and require confirmation in larger controlled trials, they represent a striking illustration of the manner in which nanoparticle delivery has enabled therapeutic modalities that were, until recently, purely aspirational.

A second emerging application concerns mucosal and needle-free immunization. The majority of pathogens invade the body through mucosal surfaces, yet conventional injectable vaccines elicit only weak mucosal immunity. Nanoparticle carriers engineered with mucoadhesive properties and appropriate surface characteristics can traverse mucosal barriers and stimulate local immune responses, offering the prospect of intranasal and oral vaccines that confer protection at the portal of pathogen entry (Zhang et al., 2019). Such formulations also promise improved patient acceptability and simplified administration, factors of considerable importance for mass immunization campaigns.

The demonstrated capacity for rapid design and manufacture of nucleic-acid nanoparticle vaccines has profound implications for pandemic preparedness. The interval between the publication of the SARS-CoV-2 genome and the initiation of clinical trials of lipid nanoparticle-mRNA vaccines was measured in weeks, an unprecedented achievement that has reframed expectations regarding response times to emerging infectious threats (Dolgin, 2021). Realising this potential at a global scale will nonetheless require sustained investment in distributed manufacturing capacity and the development of formulations with improved thermostability, thereby reducing the dependence on demanding cold-chain infrastructure that currently constrains equitable access.

Notwithstanding these advances, several formidable challenges must be addressed if the promise of nanotechnology-based vaccines is to be fully realised. The scalable and reproducible manufacture of complex multi-component nanoparticles demands sophisticated process control, and the requirement for ultra-low-temperature storage of certain lipid nanoparticle formulations poses logistical obstacles to worldwide distribution (Schoenmaker et al., 2021). Comprehensive assessment of the long-term biosafety and biodistribution of novel nanomaterials remains essential, as does the establishment of harmonised regulatory frameworks capable of evaluating these intricate products. The interrogation of nano-bio interactions, including the formation and consequences of the protein corona, will continue to inform the rational design of safer and more effective carriers. Addressing these interlocking scientific, manufacturing, and regulatory challenges constitutes the central task confronting the field in the coming decade.

Looking further ahead, the integration of artificial intelligence and high-throughput screening into nanocarrier design promises to accelerate the discovery of optimal formulations. Machine-learning models trained on large libraries of ionizable lipids and their measured delivery efficiencies are beginning to guide the synthesis of next-generation materials with improved potency and tolerability,

compressing what was once a laborious empirical process into a rapid, data-driven workflow. Parallel advances in single-cell immunology are furnishing an increasingly granular picture of how individual immune cell populations respond to particular nanocarrier features, providing the mechanistic insight required to fine-tune vaccine design. The prospect of combining these computational and immunological tools raises the realistic possibility of vaccines engineered a priori to elicit responses of defined specificity and durability against previously intractable targets, including antigenically variable viruses and heterogeneous tumours (Al-Halifa et al., 2019).

Equally consequential are the efforts to democratise access to nanoparticle vaccine technology. The concentration of manufacturing expertise and intellectual property within a small number of institutions has raised concerns regarding global equity, particularly in the context of pandemic response. Initiatives to establish regional manufacturing hubs, to simplify formulations, and to develop thermostable products that obviate the need for ultra-cold storage are therefore of paramount importance. The scientific ingenuity that produced the first generation of nanoparticle vaccines must now be matched by comparable innovation in the domains of process engineering, distribution, and regulatory science if the benefits of the technology are to be realised universally rather than remaining the preserve of well-resourced settings (Curley & Putnam, 2022).

In summary, nanotechnology has transitioned from a promising concept to an indispensable pillar of modern vaccinology. The convergence of advances in materials chemistry, immunology, and computational design has furnished a versatile toolkit for the precise engineering of vaccines against previously intractable targets. As the field matures, the integration of rational design principles with an ever-deepening understanding of the interface between nanomaterials and the immune system will be pivotal in delivering the next generation of safe, potent, and globally accessible vaccines.

References

1. Allahyari, M., & Mohit, E. (2016). Peptide/protein vaccine delivery system based on PLGA particles. *Human Vaccines & Immunotherapeutics*, 12(3), 806–828.
2. Bachmann, M. F., & Jennings, G. T. (2010). Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. *Nature Reviews Immunology*, 10(11), 787–796.

3. Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021). Nanomaterial delivery systems for mRNA vaccines. *Vaccines*, 9(1), 65.
4. Dolgin, E. (2021). The tangled history of mRNA vaccines. *Nature*, 597(7876), 318–324.
5. Dykman, L. A., & Khlebtsov, N. G. (2017). Immunological properties of gold nanoparticles. *Chemical Science*, 8(3), 1719–1735.
6. Gao, L., Li, J., & Song, T. (2022). Poly lactic-co-glycolic acid-based nanoparticles as delivery systems for enhanced cancer immunotherapy. *Frontiers in Chemistry*, 10, 973666.
7. Han, X., Zhang, H., Butowska, K., Swingle, K. L., Alameh, M. G., Weissman, D., & Mitchell, M. J. (2021). An ionizable lipid toolbox for RNA delivery. *Nature Communications*, 12(1), 7233.
8. Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. *Nature Reviews Materials*, 6(12), 1078–1094.
9. Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015). Synthetic nanoparticles for vaccines and immunotherapy. *Chemical Reviews*, 115(19), 11109–11146.
10. Kularatne, R. N., Crist, R. M., & Stern, S. T. (2022). The future of tissue-targeted lipid nanoparticle-mediated nucleic acid delivery. *Pharmaceuticals*, 15(8), 897.
11. Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., ... King, N. P. (2019). Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. *Cell*, 176(6), 1420–1431.
12. Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F. (2017). Major findings and recent advances in virus-like particle (VLP)-based vaccines. *Seminars in Immunology*, 34, 123–132.
13. Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., ... Thompson, M. (2009). Understanding biophysicochemical interactions at the nano-bio interface. *Nature Materials*, 8(7), 543–557.
14. Nguyen, B., & Tolia, N. H. (2021). Protein-based antigen presentation platforms for nanoparticle vaccines. *npj Vaccines*, 6(1), 70.
15. Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. *Nature Reviews Drug Discovery*, 17(4), 261–279.

16. Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., &Blankschtein, D. (2016). mRNA vaccine delivery using lipid nanoparticles. *Therapeutic Delivery*, 7(5), 319–334.
17. Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., ... Balachandran, V. P. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. *Nature*, 618(7963), 144–150.
18. Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021). mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. *International Journal of Pharmaceutics*, 601, 120586.
19. Silva, A. L., Soema, P. C., Slutter, B., Ossendorp, F., &Jiskoot, W. (2016). PLGA particulate delivery systems for subunit vaccines. *Human Vaccines & Immunotherapeutics*, 12(4), 1056–1069.
20. Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021). Lipid nanoparticles — from liposomes to mRNA vaccine delivery. *ACS Nano*, 15(11), 16982–17015.
21. Wang, X., Li, X., Ito, A., Watanabe, Y., Sogo, Y., Hirose, M., ... Ohno, T. (2019). Rod-shaped and substituted hydroxyapatite nanoparticles stimulating type 1 and 2 cytokine secretion. *Colloids and Surfaces B: Biointerfaces*, 174, 26–35.
22. Zhang, W., Wang, L., Liu, Y., Chen, X., Li, J., & Yang, T. (2019). Chitosan-coated PLGA nanoparticles for nasal delivery of vaccine antigens. *European Journal of Pharmaceutics and Biopharmaceutics*, 139, 1–10.
23. Chatzikleanthous, D., O'Hagan, D. T., & Adamo, R. (2021). Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens. *Molecular Pharmaceutics*, 18(8), 2867–2888.
24. Gu, P., Wusiman, A., Wang, S., Zhang, Y., Liu, Z., Hu, Y., ... Wang, D. (2019). Polyethylenimine-coated PLGA nanoparticles as a vaccine delivery system. *Carbohydrate Polymers*, 223, 115128.
25. Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021). Self-assembled mRNA vaccines. *Advanced Drug Delivery Reviews*, 170, 83–112.
26. Verbeke, R., Lentacker, I., De Smedt, S. C., &Dewitte, H. (2021). The dawn of mRNA vaccines: The COVID-19 case. *Journal of Controlled Release*, 333, 511–520.

27. Butkovich, N., Li, E., Ramirez, A., Burkhardt, A. M., & Wang, S.-W. (2021). Advancements in protein nanoparticle vaccine platforms. *WIREs Nanomedicine and Nanobiotechnology*, 13(4), e1681.
28. Curley, S. M., & Putnam, D. (2022). Biological nanoparticles in vaccine development. *Frontiers in Bioengineering and Biotechnology*, 10, 867119.
29. Fan, Y., & Moon, J. J. (2015). Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. *Vaccines*, 3(3), 662–685.
30. Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S., & Archambault, D. (2019). Nanoparticle-based vaccines against respiratory viruses. *Frontiers in Immunology*, 10, 22.